Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.

@article{Marsella2014TransfusionalIO,
  title={Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.},
  author={Maria Marsella and Caterina Borgna-Pignatti},
  journal={Hematology/oncology clinics of North America},
  year={2014},
  volume={28 4},
  pages={703-27, vi}
}
Iron overload is an inevitable consequence of blood transfusions and is often accompanied by increased iron absorption from the gut. Chelation therapy is necessary to prevent the consequences of hemosiderosis. Three chelators, deferoxamine, deferiprone, and deferasirox, are presently available and a fourth is undergoing clinical trials. The efficacy of all 3 available chelators has been demonstrated. Also, many studies have shown the efficacy of the combination of deferoxamine plus deferiprone… CONTINUE READING
Highly Cited
This paper has 31 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 131 references

Global epidemiology of haemoglobin disorders and derived service indicators.

Bulletin of the World Health Organization • 2008
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…